Home > About Us > Our History & Growth
Share
Our History

Incepta began its operation with a handful of highly skilled and dedicated professionals guided by an able leadership. Proper strategic planning, technical excellence, swift and timely decisions helped us achieve our objectives leading to much faster growth. Incepta was able to anticipate the need of the market and provide the right product at the right time. High focus on R&D investment from the very beginning made possible the introduction of quality products ahead of its competitors in most cases.

Incepta Pharmaceuticals Ltd. is now the 2nd largest company of the country and recognized as the fastest growing of the top five manufacturing company in the country. Established in the year 1999, the company has come a long way. Currently the Zirabo plant consists of several buildings with state of the art technology. Dedicated cephalosporin manufacturing building, a specialized manufacturing building for the production of lyophilized products, insulin and amino acids and newly built liquid and semisolid manufacturing building and large warehouse is also in operation.

Another multipurpose building for housing the Research & Development operation along with the canteen facility is also there. Currently all the products are coming from the plant at Zirabo. The company now produces almost all types of dosage forms covering nearly all therapeutic area.

Incepta now has one of the largest and competent sales force and large distribution network of its own, operated from 19 different locations throughout the country. A most dynamic skilled and dedicated marketing team comprising of pharmacists and doctors are at the core of the marketing operation. These highly skilled professionals play a crucial role in providing the necessary strategic guideline for the promotion of its product.

Chronology of Events:

  • 1998-00
  • 2001
  • 2002
  • 2003
  • 2004
  • 2005
  • 2006
  • 2007
  • 2008
  • 2009
  • 2010
  • 2011
  • 2012
  • 2013

December 16th 1998, the construction of the factory began.

August 1999, office operations began.

December 1999, first batch of product Neodin S 150 (Ranitidine 150 mg tablet) was produced.

January 2000, sales began formally.

February 2000, training of the first batch of medical representatives began.

April 2000, with the launching of Osartil (Losartan Potassium) the first prescription product of Incepta was launched in the market. The company started off in a new direction.

Several other first ever product, Celenta (Celecoxib), Rofenta (Rofecoxib) and Omidon (Domperidone) followed in the footsteps of Osartil.

A total of 23 new generics with 35 presentations were launched this year. 4 of these generics were first ever in Bangladesh.

By the end of 2000 Incepta was the number 31st company of the country.

There was massive restructuring throughout the company. Sales, Distribution, Marketing Strategy Department, and Factory; all were reorganized.

A total of 18 new generics with 37 presentations were launched this year. 11 of these generics were first ever in Bangladesh.

By the end of the year Incepta was ranked the 12th company of the country. The company had a phenomenal growth of 448% over the previous year (IMS).

A total of 32 new generics with 49 presentations were launched. 14 of these generics were first ever in Bangladesh.

Massive expansion project of the factory was envisioned. New office for the sales and distribution operation was also taking shape.

The company registered an excellent growth of 55.85% over the previous year. By the end of the year Incepta was ranked the 10th company of the country (IMS).

Incepta kept on introducing innovative and newer molecules to the local market. A total of 32 new generics with 48 presentations were launched. 18 of these generics were first ever in Bangladesh.

The new office (Dhanmondi) for the sales and distribution operation was inaugurated.

The company registered an excellent growth of 28.5% over the previous year (IMS).

By the end of the year Incepta was ranked the 8th company of the country (IMS).

A total of 17 new generics with 32 presentations have been launched. 6 of these generics were first ever in Bangladesh.

The company maintained an excellent growth of 48.2% over the previous year (IMS).

The ranking went up again and the company was ranked the 5th largest company of the country with the highest growth rate among the top five (IMS).

We thrived under challenge and excelled in venturing into unexplored grounds and continued to satisfy our customers. Incepta was audited and accepted as a supplier for UNICEF & UNDP. We started to supply life saving drugs to UNICEF from March, 2005.

A total of 27 new generics with 76 presentations were launched. 12 of these generics were introduced first time ever in Bangladesh.

The company maintained an excellent growth of 34.8% over the previous year (IMS).

The company was ranked 3rd largest with the highest growth among the top five (IMS).

By 2006 Incepta had positioned itself as an innovative research oriented and knowledge based pharmaceutical company specializing in analysis, design and development of new products.

Incepta successfully started overseas marketing operation from May 2006.

A total of 25 new generics with 82 presentations were launched. 9 of these generics were first ever in Bangladesh.

The company maintained an excellent growth of 31.26% over the previous year (IMS).

The company maintained the ranking of 3rd largest (IMS).

Incepta pioneered the introduction of biotech products (Human Insulin) and lyophilized products (Pantoprazole injection) in the Bangladesh pharmaceutical market. This was the first time a local pharmaceutical company produced such highly sophisticated technology product in the country.

A total of 32 new generics with 82 presentations were launched. 4 of these generics were first ever in Bangladesh.

Marketing, Sales, Distribution and Administration departments shifted to the fully owned new office premises in Tejgaon, Dhaka. The international standard head office of Incepta started operation in the new office premises on 1st October, 2007.

A marketing and sales team was setup in Myanmar headed by a country manager from the Marketing Strategy Team to promote the 35 products registered with the Myanmar FDA.

The company maintained a growth of 12.93% over the previous year (IMS).

The company held the 3rd largest ranking (IMS) among the companies.

Continued investment in our core strength that is our manufacturing plant led to recognition from European authorities and on January 11, 2008 Incepta attained European "Certificate of GMP Compliance".

40 new products with 86 presentations were introduced of which 10 were first ever in Bangladesh.

The plant received GMP certification (General formulations and Cephalosporins) from Kenyan Ministry of Health on January 21, 2008.

Incepta was also awarded GMP (Cephalosporins) from Ethiopian Ministry of Health on July 22, 2008.

Incepta registered 51 products in Mongolia on September 26, 2008 (As first Bangladeshi Company).

Incepta registered 3 products in Georgia on October 13, 2008 (As first Bangladeshi Company).

In 2008 significant number of products got registration in different countries. 19 products from Democratic Republic of Congo, 20 products from Sri Lanka, 22 products from Togo, 8 products from Hong Kong, 20 products from Mauritania, 6 products from Vietnam, 1 product in Cambodia.

The company maintained a growth of 12.10% over the previous year (IMS).

The company became the 2nd largest (IMS) among the companies operating in Bangladesh.

Incepta started venturing in the field of human vaccines and hormonal products. Construction of the Vaccine & Hormones facilities started on 1st January 2009 and 8th November 2009 respectively.

Incepta became the first Bangladeshi Company to get GMP Compliance Certificate from Turkey (Tablets, Capsules and Lyophilized products) on January 08, 2009.

Incepta achieved GMP certification from the Ministry of Health, Yemen on May 25, 2009 (Sterile and Non-sterile products).

Incepta launched 51 new products in 2009. 4 of these were first ever in Bangladesh pharmaceutical market.

The company maintained an excellent growth of 27.71% over the previous year (IMS).

The company maintained the 2nd largest (IMS) position in 2009.

Incepta was accepted and became enlisted with the Copenhagen office of UNICEF, UNDP and UNESCO as global supplier of medicine.

Incepta was awarded GMP certificate from Uganda, National Drug Authority on 5th August 2010 (Sterile Products, Non-sterile products and Cephalosporins).

Incepta launched 56 product presentations. 10 of which were first ever in Bangladesh market.

Incepta maintained the 2nd largest (IMS) position in Bangladesh pharmaceutical market in 2010. The company showed the strongest growth among the top 10 companies with a growth rate of 34.97% (IMS).

Incepta introduced Human Vaccines to the market and become the first Bangladeshi vaccine manufacturing company.

Export has emerged as a focus area for Incepta. With over 300 products registered in different countries export is now set to play more important role in the growth of the company. Currently the company exports to 37 countries of the world with many more in the pipeline.

Since starting supply of medicine to UNICEF in Bangladesh, Incepta has remained the largest supplier till today.

In 2011 the company has launched 55 products, 9 of which are first ever in Bangladesh market.

In 2012 the company has launched 52 products, 7 of which are first ever in Bangladesh market.

Up to October, 2013, the company has launched 40 products, 7 of which are first ever in Bangladesh market.


Our Growth In Comparison With Local Pharma Market (IMS* Data)

Beginning in 2000, Incepta has been launching new and innovative products at a faster pace than its competitors.

Up to October 2013 it has already launched 383 generics with a total of 686 presentations. The company produces a wide variety of dosage forms covering nearly all the major therapeutic classes.

During the last 13 years of operation Incepta launched as many as 138 new generics for the first time ever in Bangladesh. High focus on quality and timely introduction of much needed essential medications previously unavailable in the country has enabled Incepta to become the second largest pharmaceutical company of the country.


YearNo. of ProductsFirst Ever ProductIMS Rank*
201368672nd
201263172nd
201163292nd
2010594102nd
200958542nd
2008532102nd
2007451173rd
200636893rd
2005288123rd
200419865th
2003154188th
20021191410th
2001781112th
200035431st

* Intercontinental Marketing Services (IMS)